drugset / Trial / NCT00118248

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

NCT00118248

Phase 2 Completed 41 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well tanespimycin works in treating patients with inoperable locoregionally advanced or metastatic thyroid cancer. Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Timeline

Start
2004-12
Primary completion
2009-08
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject tanespimycin Unknown Intravenous